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Abstract
Background—Acute treatment of ischemic stroke patients presenting more than eight-hours
after symptom onset remains limited and largely unproven. Partial aortic occlusion using the
NeuroFlo catheter can augment cerebral perfusion in animals. We investigated the safety and
feasibility of employing this novel catheter to treat ischemic stroke patients eight-hours to 24 h
following symptom onset.
Methods—A multicenter, single-arm trial enrolled ischemic stroke patients at nine international
academic medical centers. Eligibility included age 18–85 years old, National Institutes of Health
stroke scale (NIHSS) score between four and 20, within eight-hours to 24 h after symptom onset,
and perfusion–diffusion mismatch confirmed by magnetic resonance imaging. The primary
outcome was all adverse events occurring from baseline to 30 days posttreatment. Secondary
outcomes included stroke severity on neurological indices through 90 days. This study is
registered with ClinicalTrials.gov, number NCT00436592.
Results—A total of 26 patients were enrolled. Of these, 25 received treatment (one excluded due
to aortic morphology); five (20%) died. Favorable neurological outcome at 90 days (modified
Rankin score 0–2 vs. 3–6) was associated with lower baseline NIHSS (P < 0·001) and with longer
duration from symptom discovery to treatment. There were no symptomatic intracranial
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hemorrhages or parenchymal hematomas. Asymptomatic intracranial hemorrhage was visible on
computed tomography in 32% and only on microbleed in another 20%.
Conclusions—Partial aortic occlusion using the NeuroFlo catheter, a novel collateral
therapeutic strategy, appears safe and feasible in stroke patients eight-hours to 24 h after symptom
onset.
Keywords
acute stroke therapy; cerebral blood flow; cerebral infarction; clinical trial; intervention; stroke
Introduction
Ischemic stroke remains a devastating clinical event, and few therapeutic strategies exist for
its treatment. Thrombolysis with tissue plasminogen activator (tPA) in a time window of
three-hours (1), and more recently, up to 4·5 h (2), has been demonstrated to improve
neurological outcome. Thrombectomy, which has not yet definitively proven beneficial in
randomized trials, has been increasingly used in an attempt to restore blood flow to the
ischemic tissues (3). However, <5% of patients with ischemic stroke undergo thrombolysis
(4), and <1% receive thrombectomy. Alternative therapies are urgently needed, particularly
for late-presenting patients and those with contraindications for thrombolysis. Vast efforts
have been devoted to arterial revascularization, yet few approaches have capitalized on
endogenous collateral circulation as a therapeutic approach (5,6).
Therapeutic titration of the blood flow in the descending aorta to enhance cerebral perfusion
has been tested (7). In animals, complete aortic occlusion increases blood volume,
particularly in the brain (8,9), reduces infarct size (10), and increases cerebral blood flow
(10–12). These and other blood flow manipulation studies led to the development of the
NeuroFlo catheter (Fig. 1; CoAxia, Inc., Maple Grove, MN), which increases cerebral
perfusion via partial aortic occlusion of the abdominal aorta.
In a study of NeuroFlo use in 24 patients with symptomatic vasospasm, Lylyk et al.
demonstrated persistently increased blood flow velocities in the middle cerebral artery
(MCA) by transcranial Doppler, with neurological improvement in 83% of cases (13). In 17
ischemic stroke patients, a one-hour treatment with the NeuroFlo catheter resulted in
increases in blood flow velocity in 75% of the patients, and intraprocedural neurological
improvement was noted in 67% of cases (7).
The ongoing randomized Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke
(SENTIS) trial is designed to demonstrate efficacy of NeuroFlo treatment in improving
neurological outcome in ischemic stroke patients who can undergo treatment within 14 h of
symptom onset. We were interested to know if late-presenting patients, i.e. those presenting
between eight-hours to 24 h, could safely undergo NeuroFlo treatment without an increased
risk of intracranial hemorrhage (ICH) or other adverse events (AEs). The Flo 24 study
design for late-presenting patients is congruent with many of the recommendations of the
Stroke Treatment Academic Industry Roundtable (STAIR) consortium for extended window
acute stroke therapy trials (14).
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Materials and methods
Patient selection
Patients were eligible for enrollment if they were 18–85 years and presented within eight-
hours to 24 h of the last time known normal with acute cerebral ischemia (defined as new
focal neurological deficit of presumed vascular origin), with NIHSS 4–20 (inclusive), visual
evidence of mismatch ≥20% based on locally constructed perfusion maps, and written
informed consent. Exclusion criteria were prior condition resulting in premorbid modified
Rankin score (mRS) of ≥2, acute hypodensity of more than one-third of the MCA territory,
use of any thrombolytic or thrombectomy therapy, known cerebral or aortic aneurysm,
current intracranial bleeding, blood pressure greater than 200 mmHg systolic or 120 mmHg
diastolic, or ≥5 microbleeds (MRs) seen only on magnetic resonance (MR) imaging.
Laboratory exclusions included a creatinine > 1·5× local lab normal, international
normalized ratio (INR) > 1·7, and platelet count <100 000. Cardiac exclusions included
known ejection fraction <30% or current congestive heart failure, known aortic regurgitation
≥3+, and current or recent (three-months)myocardial infarction or class III/IV angina.
Baseline evaluation required MR angiography and multiparametric MR imaging [diffusion
weighted imaging (DWI), perfusion weighted imaging (PWI), and gradient echo (GRE)
required; fluid-attenuated inversion recovery (FLAIR) optional]; CT angiography with
perfusion imaging was substituted in a few select cases.
Consenting patients meeting all selection criteria underwent an aortogramto determine aortic
anatomy. Patients with aortic diameters >24 mm or <12 mm within six-centimeters above
and below the renal ostia, evidence of aortic aneurysm, high-grade iliac stenosis, and/or
vascular tortuosity were excluded from further participation (except AE monitoring through
hospital discharge).
Treatment technique
Patients who met all selection criteria and continued to have an NIHSS of 4–20 on repeat
examination underwent Neuro-Flo treatment. The dual balloon catheter was placed in the
abdominal aorta via standard 9F femoral introduction. Cerebral flow diversion was
accomplished by approximately 70–90% occlusions immediately above and below the renal
arteries by independently inflatable balloons. During sequential inflation (infrarenal first),
suprarenal pressure was monitored via the catheter central lumen and infrarenal pressure via
the introducer side port. The balloons were inflated until each created a detectable (>5
mmHg) pressure drop with a total incremental pressure drop of at least 10–15 mmHg across
both balloons. The balloons were left inflated for 45 mins, slowly deflated, and the catheter
removed. Use of heparin was left to the discretion of the interventionalist.
Imaging and clinical end points
Patients underwent follow-up NIHSS and multimodal MR (DWI and PWI required, FLAIR
and GRE optional) within four-hours of treatment, as well as observation for AEs, including
groin hematoma or limb ischemia. NIHSS and checks for AEs were documented at 24 h and
at discharge or four-days, which ever came first. Noncontrast CT or MR was performed at
24 h and as clinically indicated for assessment of bleeding and at four-days/discharge for
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determination of final infarct volume. Neurological indices (NIHSS, Barthel Index, Glasgow
Outcome Score, and mRS) were performed at 30 and 90 days. Medical management of the
patient throughout the study period was in accordance with the Stroke Council Guidelines.
All imaging scans obtained throughout the index hospitalization were evaluated by a core
imaging laboratory (W. Dillon, University of California San Francisco). Baseline scans were
evaluated to determine the location and size of the stroke, to uniformly quantify the ≥20%
mismatch requirement for study entry, and to determine vessel stenosis/occlusion. Patients
were considered to have large vessel occlusion (LVO) if they had thrombolysis in
myocardial infarction 0 or 1 flow in the M1 segment or an M2 division of the MCA (15).
Patients were considered to have clinically relevant internal carotid artery (ICA) stenosis or
occlusion if vessel was ≥95% stenosed or occluded.
All baseline and follow-up scans were also evaluated by the core lab for evidence of ICH,
which was further classified as ‘other’, i.e., ICH not associated with hemorrhagic
transformation (HT) of the core infarct, or as one of the four categories of HT used for the
European Cooperative Acute Stroke Study (ECASS) I and ECASS II trials (16).
Statistical analysis
Categorical variables were tabulated as n (%); continuous variables were tabulated as means
with standard deviations, and medians with first and third quartiles. Univariate associations
between baseline characteristics and 90-day outcome (where ‘better’ outcome was defined
as mRS 0–2, and ‘worse’ outcome was defined as mRS 3–6) were evaluated using the
Mann–Whitney U-test for continuous variables and the Fisher’s exact test for categorical
variables.
Results
Patient population
Altogether, 26 patients were enrolled between May 2007 and September 2008; one was
excluded due to aortic anatomy and is not included in these results. No patients were lost to
follow-up. Demographic and baseline characteristics of the 25 treated patients are presented
in Table 1. Median age was 60·7 years (mean 63·4 ± 13·2), NIHSS was 12 (mean 12·8 ±
4·9), and time from last known normal to treatment was 14·2 h (mean 15·7 ± 4·2).We
calculated the time from symptom recognition or discovery (TFSD) in addition to
determining the time the patient was last known normal (TLKN).As expected, the TFSD
(median 11·1, mean 12·4 ± 5·2) was shorter than TLKN.
Core laboratory examination of baseline imaging confirmed that all patients had ≥20%
mismatch (minimum was 38%), with a PWI volume >10 ml at baseline (minimum was 54
ml). LVO (17 M1 and four M2 occlusions) was present in 21 of the 25 treated patients
(84%).Compared with the overall cohort, patients with LVO were slightly older (median
62·6 years, mean 63·0 ± 13·1), with similar NIHSS (median 12, mean 13·2 ± 4·9) and TFSD
(median 10·5 h, mean 12·2 ± 4·8).
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Notably, 15 patients (60%) had ICA occlusion ≥95%, and 13 (52%) had both LVO and ICA
occlusion. When compared with the overall cohort, patients with ICA occlusion were older
(median 64·8 years, mean 65·4 ± 13·9) and had higher NIHSS (median 16, mean 14·6 ± 4·7)
but similar TFSD (median 10·5 h, mean 11·9 ± 5·6). Table 2 provides each patient’s LVO,
ICA, and combined LVO plus ICA occlusion status, along with 90-day mRS.
To show potential baseline correlates with 90-day outcomes, Table 1 includes demographics
and baseline characteristics by 90-day outcome status (mRS 0–2 vs. >2). Worse 90-day
outcomes were significantly associated with higher NIHSS, higher infarct volume, and the
presence of ICA or ICA + LVO occlusion. Patients with better outcomes had a significantly
longer TFSD than patients with worse outcomes, but TLKN was not different. Finally, there
was a trend toward better outcomes in patients with prior TIA.
As expected, favorable 90-day outcomes (mRS 0–2) were also associated with favorable 90-
day Barthel, Glasgow, and NIHSS.
Adverse outcomes through 90 days
Among the 25 treated patients in the trial, 10 had one or more serious AEs (SAEs). SAEs
were events that were fatal, life-threatening, required or prolonged hospitalization, resulted
in neurological deterioration considered clinically relevant, or required intervention to
prevent permanent impairment as adjudicated by the Data and Safety Monitoring Board
(DSMB). There were five patient deaths (20%); in all cases, death was adjudicated by the
DSMB to be related to index stroke progression or to systemic complications associated
with index stroke rather than device-related.
Neurological AEs (AEs) included cerebral edema (2), seizure (1), new ischemic stroke (1),
and stroke progression (8). All were considered to be nonserious except for the cases of
stroke progression where the progression was adjudicated to be serious in six patients.
Vascular complications were noted in five patients: one pseudoaneurysm five-days after
NeuroFlo treatment in a patient with one prior and one subsequent groin stick (all done in
same location), one deep venous thrombosis (DVT), one hematoma, one bleeding at the
access site, and one left thigh abscess requiring only oral antibiotics in a patient with history
of frequent abscesses. The pseudoaneurysm and DVT were adjudicated as serious.
SAEs beyond those mentioned earlier include one respiratory failure, one infectious
pneumonia, two events in one patient of delirium/confusion, one ICA stenosis with
endarterectomy, one gastrointestinal bleed, one anemia, and one sepsis. Of note, no patient
experienced a serious (or symptomatic) ICH; core lab review of any ICH seen on all
patients’ imaging is summarized in the following section.
The DSMB also adjudicated device and procedure relatedness for all events. To be
adjudicated as device-related, the event was considered likely related to the NeuroFlo device
itself; to be adjudicated as procedure-related, the event was considered likely related to any
interventional procedure with a 9F sheath. No deaths were adjudicated as device or
procedure-related. There were no AEs or SAEs that were adjudicated as device-related. No
SAEs were considered to be procedure-related; three AEs were considered to be procedure-
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related (one hematoma, one bleeding at the access site, and one left thigh abscess). Of note,
there were no neurologic, cardiac, renal, or pulmonary events considered to be procedure or
device-related.
ICH
ICH data are presented by patient in Table 3 and are summarized in Table 4. None of the
ICHs (n = 13) were associated with an increase of NIHSS of four or more. No patients had
parenchymal hematoma (PH2) grade bleeding. Twelve bleeds were in the index infarction
and one was in a new infarction. Of these, 13 patients with new ICH, nine (69%) had HI1
bleeding, three (23%) had hemorrhagic infarction (HI2) with one of these in a new infarct at
seven-days, and one (8%) had HI1 within 24 h that progressed to PH1 on day 2. In the nine
patients with HI1 bleeding, five bleeds (56%) were detected only on MR (no CT
performed). In the subset of 12 patients with good 90-day outcomes, four (33·3%) had a new
asymptomatic ICH (three HI1 and one HI2). Two of these ICH were detected only on MR
(CT not performed). In the subset of 13 patients with poor 90-day outcomes, nine (69%) had
a new ICH (six HI1, two HI2, and one PH1). Three of the HI1 ICHs in patients with poor
outcome were seen only on MR (CT not performed).
Discussion
This study successfully demonstrates the feasibility and safety of applying partial aortic
occlusion using the NeuroFlo catheter in acute ischemic stroke patients who present very
late.
Not surprisingly, 90-day clinical outcome was highly correlated with baseline NIHSS score.
However, an unexpected correlation was found: patients with better outcomes had a longer
average TFSD than those with worse outcomes. Also, there was a trend toward better
outcome in patients with prior TIA.
The primary outcome of the trial, safety, was met. No AEs or SAEs were attributed to
NeuroFlo treatment. Furthermore, no patients had PH2 or symptomatic ICH (sICH). For
comparison, in Prourokinase in Acute Thromboembolic Stroke (PROACT) II, the overall
sICH rate was 10%, and among the controls (similar to Flo 24 patients), it was 2%. Within
the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution
(DEFUSE) study, the overall sICH rate was 9·5%, and even the subset of patients with
mismatch but without successful reperfusion (thus similar to Flo 24 patients) had an sICH
rate of 6·3%. It should be noted, however, that the DEFUSE investigators included any
change in NIHSS score as part of their definition for sICH (17).
New asymptomatic bleeding occurred in 13 patients (52%) in our study, and most of these
were HI1. One reason may be that nearly 40% of the bleeds were detected only on the
gradient echo (GRE) sequence on MR, and GRE may be particularly sensitive to HI1.
Second, in 56% of HI1 cases, the bleed was only detected late (beyond two-days). Since HI1
is a marker of successful reperfusion, perhaps the delayed HI1 indicated a delayed
reperfusion, possibly influenced by the NeuroFlo treatment. Third, HI may simply be a
marker of large strokes.
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This small pilot trial was not designed to test efficacy of NeuroFlo treatment and had no
control arm. Considering that our patients had a high rate of LVO, with 21 (84%) having
MCA (M1 or M2) occlusion, and that patients were treated long after stroke onset, poor
outcomes may have been predicted. In fact, 40% of patients at 30 days and 48% at 90 days
(all with mismatch) achieved a good outcome, while 24% of patients at 30 days and 44% at
90 days achieved NIHSS 0–1 or a decrease of eight points from baseline.
There may be several explanations for the favorable outcomes after late NeuroFlo treatment.
One is that the treatment itself may have stabilized an inherent progression to collateral
failure and infarct evolution in the setting of LVO. An alternative explanation hinges on our
observation that outcome was inversely related to TFSD. Perhaps later presenting patients
have inherently better collateral circulation that acts to ‘pre-serve’ the mismatch longer,
resulting in milder deficits with still-treatable tissue. The association with prior TIA may be
consistent with this hypothesis of inherently better collaterals or could conceivably be
related to some ischemic preconditioning that may have promoted development of new
collaterals. This association could also be due to chance.
This study is limited by its small size and its lack of a control arm. It is difficult in such a
single-arm study to find appropriate populations with which to compare AE rates and
outcomes, and the validity of such comparisons is uncertain. Having established the
feasibility and safety of this technique along with a signal suggesting efficacy, a randomized
trial of late flow augmentation is warranted.
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Fig. 1.
(a) Schematic of NeuroFlo; (b) NeuroFlo in the aorta.
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Table 1
Patient demographics
Characteristic All, n = 25 (%) mRS 0–2, n = 12 (%) mRS > 2, n = 13 (%) P-value
Age, years
  Median [first quartile, third quartile] 60·7 [54·1, 72·0] 61·2 [54·9, 69·9] 60·7 [53·2, 74·1] 1·000
  Mean ± standard deviation 63·4 ± 13·2 62·7 ± 10·5 64·0 ± 15·8
Gender
  Male 11 (44·0) 6 (50·0) 5 (38·5) 0·695
  Female 14 (56·0) 6 (50·0) 8 (61·5) 0·695
Race
  Caucasian 22 (88·0) 10 (83·3) 12 (92·3) 0·593
  African American 3 (12·0) 2 (16·7) 1 (7·7)
Baseline NIHSS*
  Median [first quartile, third quartile] 12·0 [9·0, 17·0] 9·0 [7·0, 11·0] 17·0 [13·0, 18·0] <0·001
  Mean ± standard deviation 12·8 ± 4·9 9·1 ± 3·0 16·2 ± 3·8
Time from symptom discovery to treatment, hours
  Median [first quartile, third quartile] 11·1 [8·8, 14·4] 14·3 [10·7, 19·9] 9·9 [8·5, 11·1] 0·030
  Mean ± standard deviation 12·4 ± 5·2 15·0 ± 6·0 10·0 ± 3·0
Time from last known normal to treatment, hours
  Median [first quartile, third quartile] 14·2 [13·2, 18·3] 16·2 [13·6, 21·1] 13·5 [11·1, 17·8] 0·123
  Mean ± standard deviation 15·7 ± 4·2 17·1 ± 4·3 14·5 ± 3·8
Baseline infarct volume, cc (17 NCT and 8 MR scans)
  Median [first quartile, third quartile] 9·1 [1·2, 22·2] 3·3 [0·0, 8·8] 21·6 [9·1, 61·7] 0·001
  Mean ± standard deviation 26·7 ± 46·0 7·6 ± 12·1 44·3 ± 58·4
Large vessel occlusion (LVO)† 21 (84·0) 9 (75·0) 12 (92·3) 0·322
ICA occlusion‡ 15 (60·0) 4 (33·3) 11 (84·6% 0·015
LVO + ICA occlusion 13 (52·0) 3 (25) 10 (76·9) 0·017
History of hypertension 21 (84·0) 11 (91·7) 10 (76·9) 0·593
History of diabetes 8 (32·0) 3 (25·0) 5 (38·5) 0·673
Current smoker 10 (40·0) 3 (25·0) 7 (53·8) 0·226
Prior stroke 4 (16·0) 3 (25·0) 1 (7·7) 0·322
Prior TIA 3 (12·0) 3 (25·0) 0 (0·0) 0·096
History of atrial fibrillation 4 (16·0) 1 (8·3) 3 (23·1) 0·593
History of peripheral vascular disease 1 (4·0) 1 (8·3) 0 (0·0) 0·480
History of PTCA, CABG, and/or MI 2 (8·0) 0 (0·0) 2 (15·4) 0·480
*
If baseline NIHSS is not available, the presenting NIHSS was substituted.
†
Large vessel occlusion (LVO) = TIMI 0 or 1 flow in M1 or M2, per PROACT II definition (0).
‡
ICA Occlusion = ≥95% stenosis or occlusion in internal carotid artery on side of stroke.
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Table 2
Baseline vessel occlusion status, by patient, by 90-day outcome
Patient ID no. 90-day mRS LVO per PROACT II definition ICA occlusion > 95% Both LVO and ICA occlusion
18 0 M1 No No
3 1 M1 Yes Yes
9 1 M1 Yes Yes
10 1 M1 No No
11 1 no No No
21 1 M2 No No
22 1 no No No
23 1 M2 Yes Yes
24 1 M2 No No
5 2 M2 No No
6 2 no Yes No
20 2 M1 No No
7 3 M1 Yes Yes
16 3 M1 No No
25 3 M1 Yes Yes
1 4 M1 Yes Yes
2 4 M1 Yes Yes
13 4 M1 Yes Yes
15 4 M1 Yes Yes
14 5 M1 No No
17 6 (d 3) M1 Yes Yes
4 6 (d 10) no Yes No
8 6 (d 13) M1 Yes Yes
12 6 (d 37) M1 Yes Yes
19 6 (d 38) M1 Yes Yes
mRS scoring: 0 = no deficits, 6 = death, with days to death in parentheses.
Large vessel occlusion (LVO) = TIMI 0 or 1 flow in the M1 segment or an M2 division of the middle cerebral artery, per PROACT II definition
(0).
ICA occlusion = ≥95% stenosis or occlusion in the ICA ipsilateral to the stroke.
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Table 4
Posttreatment intracranial hemorrhage (ICH) summary
All
n = 25 (%)
mRS 0–2
n = 12 (%)
mRS 3–6
n = 13 (%) P-value
New ICH through 24 h n 7/25 (28) 2/12 (16·7) 5/13 (38·5) 0·378
All new ICH (four-hours through nine-days) n 13/25 (52·0) 4/12 (33·3) 9/13 (69·2) 0·115
All new ICH confirmed on CT (four-hours through nine-days) n 8/25 (32·0) 2/12 (16·7) 6/13 (46·2) 0·201
Categories for all new ICH on any scan 9 HI1 3 HI1 6 HI1 0·089
3 HI2 1 HI2 1 HI2
1 PH1 0 PH1 1 PH1
0 other 0 other 0 other
ICH categories: other = ICH not associated with hemorrhagic transformation of the core infarct; HI1 (petechial infarction without space-occupying
effect): HI2 (more confluent petechiae); PH1 (≤30% of infarcted area with some mild space-occupying effect); PH2 (>30% of the infarcted area
with significant space-occupying effect, or clot remote from infarcted area).
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